Sugi Predict

Sugi Predict / Compounds / SCHEMBL20137006

SCHEMBL20137006

SCHEMBL20137006

CC1(CBr)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NR1H2 P55055 2/20 0.41
▸ RORC P51449 2/20 0.38
▸ HPGD P15428 1/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ CTSK P43235 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ DDB1 Q16531 1/20 0.35
▸ CRBN Q96SW2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28563637 0.87 USP2 (0.42) USP2SMN1; SMN2NR1H2RORCHPGD
SCHEMBL28914034 0.84 HPGD (0.41) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL15262928 0.84 NR1H2 (0.46) USP2SMN1; SMN2NR1H2RORCHPGD
SCHEMBL24650694 0.84 USP2 (0.44) USP2SMN1; SMN2NR1H2RORCHPGD
SCHEMBL15334938 0.84 USP2 (0.44) USP2SMN1; SMN2NR1H2RORCHPGD
SCHEMBL31129641 0.83 USP2 (0.49) USP2SMN1; SMN2NR1H2HPGDEPHX2
SCHEMBL20136928 0.82 USP2 (0.43) USP2SMN1; SMN2NR1H2RORCHPGD
SCHEMBL29491132 0.82 USP2 (0.43) USP2SMN1; SMN2NR1H2RORCHPGD
SCHEMBL21906695 0.82 USP2 (0.43) USP2SMN1; SMN2NR1H2RORCHPGD
SCHEMBL31230947 0.82 USP2 (0.43) USP2SMN1; SMN2NR1H2RORCHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368666-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES INC (US) 2025-12-04 — — US disclosed
EP-4547656-A1 INDAZOLE COMPOUNDS Tyra Biosciences, Inc. (US) 2025-05-07 — — EP disclosed
CN-119731165-A Indazole compounds 泰拉生物科学公司 2025-03-28 — — CN disclosed
CN-114163437-B Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors 阿雷生物药品公司 2025-03-04 — — CN disclosed
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 — — US disclosed
US-20240391927-A1 UNIFIED SYNTHETIC ENTRY TO AZASPIRO 3.N ALKANES The Florida State University Research Foundation, Inc. 2024-11-28 — — US disclosed
CN-119013277-A TYK2 degrading agent and application thereof 凯麦拉医疗公司 2024-11-22 — — CN disclosed
US-20240299387-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER BLUEPRINT MEDICINES CORPORATION 2024-09-12 — — US disclosed
EP-4423086-A1 TYK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-09-04 — — EP disclosed
US-11998545-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2024-06-04 — — US disclosed
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-01-08 — — US disclosed
US-10144734-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-12-04 — — US disclosed
US-10137124-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-11-27 — — US disclosed
US-10112942-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-10-30 — — US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 — — US disclosed
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299387-A1 HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER EGFR, ERBB2, ERBB4 USP2 3449/4885SMN1; SMN2 4608/4885NR1H2 3224/4885
US-20180134702-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3575/4885SMN1; SMN2 833/4885NR1H2 2951/4885
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A USP2 270/4885SMN1; SMN2 1593/4885NR1H2 3851/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 USP2 3655/4885SMN1; SMN2 646/4885NR1H2 3440/4885
US-20240391927-A1 UNIFIED SYNTHETIC ENTRY TO AZASPIRO 3.N ALKANES AZI2, SLC29A2, SLCO4C1 USP2 2641/4885SMN1; SMN2 1519/4885NR1H2 1163/4885
US-10144734-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 USP2 3655/4885SMN1; SMN2 646/4885NR1H2 3440/4885
US-10112942-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF USP2 3575/4885SMN1; SMN2 833/4885NR1H2 2951/4885
US-20250368666-A1 INDAZOLE COMPOUNDS FGFR1, FGFR3, FGFR2 USP2 3629/4885SMN1; SMN2 2326/4885NR1H2 473/4885
US-20180133200-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3575/4885SMN1; SMN2 833/4885NR1H2 2951/4885
US-10172845-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 USP2 3655/4885SMN1; SMN2 646/4885NR1H2 3440/4885
US-11998545-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF USP2 3575/4885SMN1; SMN2 833/4885NR1H2 2951/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 USP2 3655/4885SMN1; SMN2 646/4885NR1H2 3440/4885
US-10137124-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF USP2 3575/4885SMN1; SMN2 833/4885NR1H2 2951/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 USP2 3655/4885SMN1; SMN2 646/4885NR1H2 3440/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF USP2 3575/4885SMN1; SMN2 833/4885NR1H2 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.